# ![@OceanBlueInvest Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::2017244983351263232.png) @OceanBlueInvest Blue Oceans

Blue Oceans posts on X about market cap, strong, global, ai the most. They currently have [--] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::2017244983351263232/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2017244983351263232/c:line/m:interactions.svg)

- [--] Week [-----] +84,117%

### Mentions: [--] [#](/creator/twitter::2017244983351263232/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2017244983351263232/c:line/m:posts_active.svg)


### Followers: [--] [#](/creator/twitter::2017244983351263232/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2017244983351263232/c:line/m:followers.svg)

- [--] Week [--] +650%

### CreatorRank: [---------] [#](/creator/twitter::2017244983351263232/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2017244983351263232/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  66.67% [stocks](/list/stocks)  47.22% [technology brands](/list/technology-brands)  11.11% [cryptocurrencies](/list/cryptocurrencies)  11.11%

**Social topic influence**
[market cap](/topic/market-cap) #694, [strong](/topic/strong) 13.89%, [global](/topic/global) #417, [ai](/topic/ai) 13.89%, [health](/topic/health) 11.11%, [stocks](/topic/stocks) 11.11%, [market](/topic/market) #2573, [growth](/topic/growth) #275, [$prta](/topic/$prta) #1, [$nrxp](/topic/$nrxp) #2

**Top accounts mentioned or mentioned by**
[@thenewceo_](/creator/undefined)

**Top assets mentioned**
[Prothena Corporation plc Ordinary Shares (PRTA)](/topic/$prta) [Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) [ARS Pharmaceuticals, Inc. (SPRY)](/topic/$spry) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Apple, Inc. (AAPL)](/topic/$aapl) [Revolution Medicines, Inc. (RVMD)](/topic/$rvmd) [Acrivon Therapeutics, Inc. (ACRV)](/topic/$acrv) [AST SpaceMobile, Inc. Class A Common Stock (ASTS)](/topic/$asts) [Auroracoin (AUR)](/topic/$aur) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Neurocrine Biosciences, Inc. (NBIX)](/topic/$nbix) [iRhythm Technologies, Inc (IRTC)](/topic/$irtc) [Praxis Precision Medicines, Inc. (PRAX)](/topic/$prax) [Scholar Rock Holding Corporation Common Stock (SRRK)](/topic/$srrk) [Alphabet Inc Class A (GOOGL)](/topic/$googl) [Atlassian Corporation PLC (TEAM)](/topic/$team) [Microsoft Corp. (MSFT)](/topic/$msft) [Metadium (META)](/topic/$meta) [Adobe, Inc. (ADBE)](/topic/$adbe) [Now Coin (NOW)](/topic/$now) [Pinterest, Inc. (PINS)](/topic/$pins) [monday.com Ltd. (MNDY)](/topic/$mndy) [Docusign Inc (DOCU)](/topic/$docu) [Applied Optoelectronics, Inc. (AAOI)](/topic/$aaoi) [Denali Therapeutics Inc. Common Stock (DNLI)](/topic/$dnli) [Crinetics Pharmaceuticals, Inc. (CRNX)](/topic/$crnx) [Huma Finance (HUMA)](/topic/$huma) [Palantir Technologies Inc. (PLTR)](/topic/$pltr) [Datadog Inc (DDOG)](/topic/$ddog) [Snowflake Inc. (SNOW)](/topic/$snow) [Rigetti Computing, Inc. Common Stock (RGTI)](/topic/$rgti) [IonQ, Inc. (IONQ)](/topic/$ionq) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) [Femasys, Inc. (FEMY)](/topic/$femy) [NVIDIA Corp. (NVDA)](/topic/$nvda) [Credo Technology Group Holding Ltd (CRDO)](/topic/$crdo) [Astera Labs, Inc. (ALAB)](/topic/$alab)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$IRTC reported about 30.7% revenue growth in Q3 [----] reaching roughly $193 million as adoption of its digital cardiac monitoring platform continues to expand across clinical workflows and value based care. The company operates in ambulatory and arrhythmia monitoring part of a market already estimated around $7 to $8 billion and expected to grow as healthcare shifts toward continuous data driven detection and earlier diagnosis. When steady top line momentum meets a structurally expanding healthcare market the potential for scalable long term growth becomes more compelling."  
[X Link](https://x.com/OceanBlueInvest/status/2020489845282390395)  2026-02-08T13:28Z [--] followers, [--] engagements


"Brain health is one of the hardest areas in medicine yet these show strong revenue growth estimated this year: $PRTA +1183% - therapies targeting Alzheimers and neurodegeneration. $NRXP +848% - treatments for depression and severe mental illness. Neurology breakthroughs could be transformational. https://twitter.com/i/web/status/2022378552776167483 https://twitter.com/i/web/status/2022378552776167483"  
[X Link](https://x.com/OceanBlueInvest/status/2022378552776167483)  2026-02-13T18:33Z [--] followers, [--] engagements


"Small-cap biotech momentum names on my radar: $CLGN 85.8% growth PS [---] Uses plant-based collagen for regenerative medicine and tissue repair. $IOVA 59.4% growth PS [---] Leader in tumor-infiltrating lymphocyte (TIL) cancer immunotherapies. $SPRY 120.0% growth PS [---] Developing emergency treatments for severe allergic reactions. https://twitter.com/i/web/status/2022401628553502900 https://twitter.com/i/web/status/2022401628553502900"  
[X Link](https://x.com/OceanBlueInvest/status/2022401628553502900)  2026-02-13T20:04Z [--] followers, [---] engagements


"$BBIO delivered roughly 129% revenue growth in [----] a rare acceleration that signals the shift from pipeline story toward real commercial traction. Its lead programs target neurological and immune conditions with large addressable markets. The global migraine market alone exceeds $7B annually while broader neurology and immune categories reach into the tens of billions. When rapid growth meets meaningful market size scalable long-term value can begin to emerge. One to watch from a long-term perspective. https://twitter.com/i/web/status/2020488255184015821"  
[X Link](https://x.com/OceanBlueInvest/status/2020488255184015821)  2026-02-08T13:21Z [--] followers, [---] engagements


"3 biotech stocks with massive projected revenue growth next year I'm watching: $PRAX (+29535%) - developing precision therapies for neurological disorders like epilepsy and major depressive disorder. $SRRK (+21831%) - focused on treatments for rare neuromuscular diseases such as spinal muscular atrophy. $INO (+23060%) - advancing DNA-based immunotherapies and vaccines targeting cancers and infectious diseases. Explosive growth potential + breakthrough medicine = classic high-risk high-reward biotech. https://twitter.com/i/web/status/2021624959777321375"  
[X Link](https://x.com/OceanBlueInvest/status/2021624959777321375)  2026-02-11T16:38Z [--] followers, [---] engagements


"Big Tech $MSFT $GOOGL $META $AAPL are currently trading in a completely different universe at [----] FCF. Meanwhile many software names like $ADBE $TEAM $NOW $PINS $MNDY $DOCU are getting obliterated down to [---] FCF. Which one are you buying the dip on right now 👇"  
[X Link](https://x.com/OceanBlueInvest/status/2021671825290166776)  2026-02-11T19:44Z [--] followers, [---] engagements


"$AAOI is riding the infrastructure wave as bandwidth demand keeps compounding. AI data-center optical demand is accelerating capacity expansion across hyperscalers. Revenue growth YoY: +102% Market cap: $2.9B"  
[X Link](https://x.com/OceanBlueInvest/status/2022657074535240190)  2026-02-14T13:00Z [--] followers, [--] engagements


"Biotech names forecasting huge revenue expansion next year: $MREO (+6363%) developing therapies for rare diseases and oncology with a focus on unmet medical needs. $DNLI (+3897%) targeting neurodegenerative conditions like Parkinsons and Alzheimers disease. $NTRB (+3394%) working on abuse-deterrent transdermal treatments and innovative drug delivery solutions. Big science. Big numbers. Big risk. https://twitter.com/i/web/status/2021625599291240816 https://twitter.com/i/web/status/2021625599291240816"  
[X Link](https://x.com/OceanBlueInvest/status/2021625599291240816)  2026-02-11T16:41Z [--] followers, [----] engagements


"Cancer is still one of medicines biggest challenges. These companies show major revenue growth expected this year: $RVMD +750% - targeted treatments for hard-to-treat tumors. $ACRV +805% - precision oncology matched to each patient. Oncology breakthroughs often create the largest biotech winners. https://twitter.com/i/web/status/2021661578907820537 https://twitter.com/i/web/status/2021661578907820537"  
[X Link](https://x.com/OceanBlueInvest/status/2021661578907820537)  2026-02-11T19:04Z [--] followers, [---] engagements


"Hospital infections and critical care still lack enough solutions. Watching these with revenue growth estimated this year: $IFRX +1054% immune therapies for life-threatening inflammation. $CTXR +148% treatments for severe hospital infections. Acute care innovation saves lives fast. #Investing https://twitter.com/i/web/status/2022262555167637603 https://twitter.com/i/web/status/2022262555167637603"  
[X Link](https://x.com/OceanBlueInvest/status/2022262555167637603)  2026-02-13T10:52Z [--] followers, [--] engagements


"These biotech stocks are showing strong estimated revenue growth this year and Im watching closely: $CRNX +893% drugs for rare hormone disorders where treatment options are still limited. $HUMA +731% lab-grown blood vessels that could change surgery and trauma care. Rare disease and regenerative medicine both target huge unmet needs. https://twitter.com/i/web/status/2022270711872553228 https://twitter.com/i/web/status/2022270711872553228"  
[X Link](https://x.com/OceanBlueInvest/status/2022270711872553228)  2026-02-13T11:24Z [--] followers, [---] engagements


"Space autonomy and robotics companies growing at hyper speed. $ASTS 314% est. growth [----] $30B Mkt cap Building the first space-based cellular broadband network. Global telecom TAM measured in trillions. Catalyst: commercial satellite launches and carrier deals. $AUR 586% growth $8B Autonomous trucking software for long-haul freight. Targets the multi-hundred-billion trucking industry. Catalyst: driverless freight commercialization milestones. $OUST 36% growth $1B Lidar sensors powering robots vehicles and automation. Exposure to autonomy + industrial robotics expansion. Catalyst: rising"  
[X Link](https://x.com/anyuser/status/2022380928807428148)  2026-02-13T18:42Z [--] followers, [---] engagements


"High-growth biotech stocks Im watching closely: $ACRV 805.3% revenue growth PS N/A Precision oncology company using proteomics to match patients with targeted cancer therapies. $AUTL 84.5% growth PS [---] Develops CAR-T cell therapies for blood cancers with next-gen safety controls. $PHAT 80.4% growth PS [---] Focused on treatments for gastrointestinal diseases like GERD with novel acid blockers. https://twitter.com/i/web/status/2022401468251410781 https://twitter.com/i/web/status/2022401468251410781"  
[X Link](https://x.com/OceanBlueInvest/status/2022401468251410781)  2026-02-13T20:04Z [--] followers, [--] engagements


"Inflammation immunity and infection are still far from solved. These show powerful revenue growth projected for this year: $IFRX +1054% severe inflammatory disease treatments. $ITRM +948% antibiotics for resistant infections. Both address urgent global health threats"  
[X Link](https://x.com/OceanBlueInvest/status/2022402601971782101)  2026-02-13T20:08Z [--] followers, [---] engagements


"Brain health is one of the hardest areas in medicine yet these show strong revenue growth estimated this year: $PRTA +1183% therapies targeting Alzheimers and neurodegeneration. $NRXP +848% treatments for depression and severe mental illness. Neurology breakthroughs could be transformational. https://twitter.com/i/web/status/2022402867907219799 https://twitter.com/i/web/status/2022402867907219799"  
[X Link](https://x.com/OceanBlueInvest/status/2022402867907219799)  2026-02-13T20:09Z [--] followers, [--] engagements


"AI software platforms compounding quietly: $PLTR 40% est. growth [----] $300B Enterprise AI operating system. Catalyst: commercial adoption. $SNOW 24% $59B AI data cloud platform. Catalyst: AI workload monetization. $DDOG 20% $44B Cloud observability. Catalyst: AI infra complexity. Software still wins long term. https://twitter.com/i/web/status/2022403184447087033 https://twitter.com/i/web/status/2022403184447087033"  
[X Link](https://x.com/OceanBlueInvest/status/2022403184447087033)  2026-02-13T20:11Z [--] followers, [---] engagements


"$ABP is trying to make T-cell therapies work in solid tumors one of oncologys hardest unsolved problems. Early trials will show whether this is real progress or just another idea. Revenue growth YoY: +50% Market cap: $2.3M"  
[X Link](https://x.com/OceanBlueInvest/status/2022657268399976508)  2026-02-14T13:00Z [--] followers, [--] engagements


"Quantum computing leaders with explosive revenue scaling: $RGTI 179% est. growth in [----] $5B mkt. cap Develops superconducting quantum processors for complex simulations. Targets a future compute market potentially worth tens of billions. Catalyst: improved qubit fidelity and enterprise pilots. $IONQ 81% growth $11B Cloud-accessible trapped-ion quantum systems. Focused on commercial + government quantum adoption. Catalyst: expanding contract backlog and real workloads. $QBTS 55% growth $7B Quantum annealing for logistics and optimization problems. Large opportunity across transportation"  
[X Link](https://x.com/OceanBlueInvest/status/2022657908257751217)  2026-02-14T13:03Z [--] followers, [--] engagements


"Rare disease innovation continues accelerating with major revenue growth expected this year: $ABEO +1589% gene therapy for rare childhood disorders. $KALV +204% treatments for rare swelling diseases. Small patient groups but life-changing therapies"  
[X Link](https://x.com/OceanBlueInvest/status/2022659399328862398)  2026-02-14T13:09Z [--] followers, [--] engagements


"Undervalued biotech growth plays: $CLOV 43.9% growth PS [---] Tech-driven Medicare Advantage insurer using data to improve care. $VXRT 50.0% growth PS [---] Oral vaccine platform targeting respiratory and GI viruses. $XAIR 179.8% growth PS [---] Nitric-oxide respiratory therapies for lung disease. Interesting risk/reward"  
[X Link](https://x.com/OceanBlueInvest/status/2022659827684512130)  2026-02-14T13:10Z [--] followers, [---] engagements


"Small-cap biotech momentum names on my radar: $CLGN 85.8% growth PS [---] Uses plant-based collagen for regenerative medicine and tissue repair. $IOVA 59.4% growth PS [---] Leader in tumor-infiltrating lymphocyte (TIL) cancer immunotherapies. $SPRY 120.0% growth PS [---] Developing emergency treatments for severe allergic reactions. Watching closely. https://twitter.com/i/web/status/2022660369643159796 https://twitter.com/i/web/status/2022660369643159796"  
[X Link](https://x.com/OceanBlueInvest/status/2022660369643159796)  2026-02-14T13:13Z [--] followers, [---] engagements


"Biotech innovators scaling fast: $RVMD 750.4% growth PS N/A Precision oncology targeting RAS-mutated cancers. $URGN 110.7% growth PS [----] Localized drug delivery for urologic cancers. $TGTX 46.4% growth PS [---] Immunotherapy treatments for multiple sclerosis and lymphoma. High volatility high upside"  
[X Link](https://x.com/OceanBlueInvest/status/2022707719619190835)  2026-02-14T16:21Z [--] followers, [---] engagements


"Womens health and fertility remain under-served globally. These companies show solid revenue growth projected for this year: $FEMY +147% reproductive health solutions. $NIVF +1233% fertility and IVF services. Long-term demographic demand could matter here"  
[X Link](https://x.com/OceanBlueInvest/status/2022709661196038167)  2026-02-14T16:28Z [--] followers, [--] engagements


"Space autonomy and robotics growth stories accelerating: $AUR 586% est. growth $8B Develops autonomous trucking software for the multi-hundred-billion freight industry. Catalyst: commercial driverless freight deployment. $ASTS 314% $30B Building a space-based cellular broadband network addressing the global telecom market. Catalyst: satellite launches enabling real coverage. $OUST 36% $1B Produces lidar sensors for robots vehicles and industrial automation. Catalyst: scaling industrial and mobility deployments. Physical-world AI is becoming investable"  
[X Link](https://x.com/OceanBlueInvest/status/2022710884942897330)  2026-02-14T16:33Z [--] followers, [---] engagements


"Semiconductor leaders enabling the AI compute boom: $NVDA 54% est. growth [----] $4.5T mkt cap. Designs GPUs that train and run modern AI models. Catalyst: next-gen chips and sovereign AI spending. $CRDO 38% est. growth [----] $22B mkt cap. High-speed optical connectivity linking AI chips in data centers. Catalyst: scaling AI cluster bandwidth. $ALAB 36% est. growth [----] $22B mkt cap. Connectivity silicon moving data across AI hardware. Catalyst: hyperscaler design wins. AI hardware demand remains structurally strong"  
[X Link](https://x.com/OceanBlueInvest/status/2022711017835307121)  2026-02-14T16:34Z [--] followers, [--] engagements


"Undervalued healthcare disruptors: $CLOV 43.9% growth PS [---] AI-enabled Medicare Advantage insurer improving care efficiency. $EVH 26.9% growth PS [---] Value-based specialty care management platform. $VSEE 30.0% growth PS [---] Telehealth infrastructure and virtual care delivery. Low multiples big theme"  
[X Link](https://x.com/OceanBlueInvest/status/2022711495096766842)  2026-02-14T16:36Z [--] followers, [---] engagements


"$ABUS is chasing something bigger than treatment a functional cure for chronic hepatitis B. If mid-stage data holds the entire HBV landscape could shift. Revenue growth YoY: +117% Market cap: $771.2M"  
[X Link](https://x.com/OceanBlueInvest/status/2022711945380479413)  2026-02-14T16:38Z [--] followers, [--] engagements


"Why $MDGL is a biotech name to watch for [----] Madrigal Pharmaceuticals is targeting MASH a serious liver disease with significant unmet need led by its first-in-class therapy Rezdiffra. Revenue growth expected this year: +54% Multi-billion-dollar market potential if adoption scales Market cap still small compared to metabolic leader $LLY suggesting meaningful upside if execution continues A developing commercial story worth following as the MASH market begins to take shape. https://twitter.com/i/web/status/2021629698820780405 https://twitter.com/i/web/status/2021629698820780405"  
[X Link](https://x.com/OceanBlueInvest/status/2021629698820780405)  2026-02-11T16:57Z [--] followers, [---] engagements


"Precision oncology continues gaining momentum. These companies show high revenue growth projected this year: $BCTX +381% - immune-based breast cancer therapy. $NUVB +191% - targeted cancer medicines. Personalized cancer care is a long-term theme with many potential winners"  
[X Link](https://x.com/OceanBlueInvest/status/2021850612359483636)  2026-02-12T07:35Z [--] followers, [---] engagements


"Gene and cell therapy hyper-growers Im watching with strong estimated revenue growth this year: $CRSP +1478% gene editing aiming to cure inherited disease. $MGTX +569% gene therapy designed to fix disease at the DNA level. Curative medicine could redefine healthcare economics. https://twitter.com/i/web/status/2022270999404650657 https://twitter.com/i/web/status/2022270999404650657"  
[X Link](https://x.com/OceanBlueInvest/status/2022270999404650657)  2026-02-13T11:25Z [--] followers, [---] engagements


"AI infrastructure platforms scaling revenue fastest into 2026: $CRWV 136% est. revenue growth this year $50B market cap Builds AI-focused cloud infrastructure rented to hyperscalers. Addressing a multi-hundred-billion-dollar AI compute market. Catalyst: continued surge in enterprise and sovereign AI demand. $APLD 62% growth $10B Develops high-performance data centers for AI and HPC workloads. TAM tied to global AI infrastructure build-out. Catalyst: new long-term compute hosting contracts. $SMCI 22% growth $18B Designs liquid-cooled AI servers used by hyperscalers. Riding the expanding AI"  
[X Link](https://x.com/OceanBlueInvest/status/2022311165032861764)  2026-02-13T14:05Z [--] followers, [--] engagements


"Vision loss and eye disease remain massive unsolved problems. These names show strong revenue growth estimated for this year: $OCS +691% new therapies for serious eye conditions. $LENZ +195% treatments designed to improve eyesight. Aging populations could drive long-term demand here. https://twitter.com/i/web/status/2021661798454505718 https://twitter.com/i/web/status/2021661798454505718"  
[X Link](https://x.com/OceanBlueInvest/status/2021661798454505718)  2026-02-11T19:05Z [--] followers, [---] engagements


"$AAPL remains the consumer tech fortress with ecosystem lock-in still printing cash. On-device AI and services monetization are setting up the next upgrade cycle. Revenue growth YoY: +11% Market cap: $3.9T"  
[X Link](https://x.com/OceanBlueInvest/status/2022712295185359175)  2026-02-14T16:39Z [--] followers, [--] engagements


"Cloud networking & infrastructure software: $NET [----] estimated revenue growth 28% $65B cap Global edge cloud platform. $ORCL 29% growth $447B cap Enterprise cloud & databases. $IOT 20% growth $16B cap IoT fleet & operations platform"  
[X Link](https://x.com/OceanBlueInvest/status/2022716129056043335)  2026-02-14T16:54Z [--] followers, [--] engagements


"$NBIX is one of the more underappreciated stories in biotech (+24% YoY revenue growth). Revenue has surged over the past few years but the stock hasnt followed. As a result its now trading at an attractive valuation of just 5.2x price to sales. They focus on neurological disorders with blockbuster drug Ingrezza generating $2B+ in annual sales and a growing pipeline on top. Profitable biotech real growth reasonable valuation. https://twitter.com/i/web/status/2018345530116411569 https://twitter.com/i/web/status/2018345530116411569"  
[X Link](https://x.com/OceanBlueInvest/status/2018345530116411569)  2026-02-02T15:27Z [--] followers, [--] engagements


"Four mid-cap pharma stocks Im buying for hypergrowth and their annual revenue growth: $ALNY (+70%) gene-silencing drugs for rare genetic diseases $NBIX (+24%) profitable neuroscience leader with blockbuster sales $BBIO (+125%) pipeline-driven rare disease platform hitting scale $MDGL (+435%) breakthrough therapy for NASH with massive unmet demand https://twitter.com/i/web/status/2018578722580758553 https://twitter.com/i/web/status/2018578722580758553"  
[X Link](https://x.com/OceanBlueInvest/status/2018578722580758553)  2026-02-03T06:54Z [--] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing